Abstract
A review of the literature about the presence of visual field disturbance associated with the use of vigabatrin as an antiepileptic. Taking into account that there exists warnings to prescribe vigabatrine derived from visual defects, we present a non - systematic review that describe the main aspects regard to prevalence, risk factors, pathophisiology and following of this side effect. Prevalence of occurrence of retinopathy varies according to differentseries, and risk factors such as use of maximum dose, cumulative dose and age, so that this effect is considered idiosyncratic. Periodic ophthalmologic supervision is recommended.
References
Krämer G. Vigabatrin. In S. Shorvon, E. Perucca, D. Fish y E. Dodson, editors, The treatment of epilepsy, second edition. Oxford: Blackwell Science 2004; 540-547.
Mackay M, Weiss S, Snead O. Treatment of infantile spasms: an evidence-bases approach. Int Rev Neurobiol 2002; 49: 157-184.
Eke T, Talbot J, Lawden M. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180-181.
Malmgrem K, Ben-Menachem E, Frisen L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001; 42: 609-615.
Mc Donagh J, Stephen L, Dolan F, Paks S, Dutton G, Kelly K et al. Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 2003; 61: 1690-1694.
Manuchehri K, Goodman S, SIvites L, Nightingale S. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 2000; 84: 499-505.
Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: Epidemiology and Therapeutic Implications. CNS Drugs 2001; 15(3): 217-230.
Emma J, Roff H, Sarah L, Hosking, Betts T. The effect of antiepileptic drug on visual performance. Seizure 2004; 13: 113-128.
Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, Simonutti M et al. Taurine Deficiency Is a Cause of Vigabatrin-Induced Retinal Phototoxicity. Ann Neurol 2009; 65: 98-107.
Kinirons P, Cavalleri G, Singh R, Shahwan A, Acheson J, Wood N. A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Research 2006; 70: 144-152.
Mumford J, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmac 1989; 27: 101-107.
Nousiainen I, Mäntyjärvi M, Kälviäinen R. No reversion in vigabatrin-associated visual field defects. Neurology 2001; 57: 1916-1917.
Best J, Acheson J. The natural historyof Vigabatrin associated visual field defects in patients electing to continue their medication. Eye 2005; 19: 41-44.
Conway M, Cubbidge P, Hosking S. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008; 49(1): 108-116.
Gaily E, Johnsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009; 50(2): 206-216.
Werth R, Schädler G. Visual Field Loss in Young Children and Mentally Handicapped Adolescents Receiving Vigabatrin. Invest Ophtalmol Vis Sci 2006; 47(7): 3028-35.
JeoSng, HyoSook A, Tae-Sung K. Vigabatrin and Visual Field Defects in Pediatric Epilepsy Patients. J Korean Med Sci 2006; 21: 728-32.
Agrawal S, Mayer L, Hansen R, Fulton A. Visual Fields in Young Children Treated with Vigabatrin. Optometry and Vision Science 2009; 86(6): 767-773.
Zgorzalewicz M, Galas-Zgorzalewicz B. Visual and auditory evoked potentials during long-term vigabatrin treatment in children and adolescents with epilepsy. Clinical Neurophysiology 2000; 111: 2150-2154.
Willmore L, Abelson B, Ben-Menachem E, Pellock J, Shields W. Vigabatrin: Update 2008, Critical review and invited commentary. Epilepsia 2009; 50(2): 163-173.
Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual field defect. Lancet 1999; 81: 41-46.
Giordano L, Valseriati D, Vignoli A, Morescalchi F, Gandolfo E. Another case of reversibility of visual-defect induced by vigabatrin monotherapy: ¿is young age a favorable factor? Neurol Sci 2000; 21: 185-186.
Suárez-Baraza J, Suárez-Parra S. Retinopatía tóxica por vigabatrín. Arch Soc Esp Oftalmol 2007; 82: 711-714.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.